Vladimir N. Chouljenko

Dr. Vladimir N. Chouljenko


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2021 in Viruses
Verified
Journal Article
Open access
PDF file
NJNithya Jambunathan
Nithya Jambunathan
CCCarolyn Marie Clark
Carolyn Marie Clark
FMFarhana Musarrat
Farhana Musarrat
VCVladimir N. Chouljenko
Vladimir N. Chouljenko
JRJared Rudd
Jared Rudd
KKKonstantin G Kousoulas
Konstantin G Kousoulas
Herpes simplex virus type-1 (HSV-1) and type-2 (HSV-2) are prototypical alphaherpesviruses that are characterized by their unique properties to infect trigeminal and dorsal root ganglionic neurons, respectively, and establish life-long latent infections. These viruses initially infect mucosal epithelial tissues and subsequently spread to neurons. They are associated with a significant disease spectrum, including orofacial and ocular infections for HSV-1 and genital and neonatal infections for HSV-2. Viral glycoproteins within the virion envelope bind to specific cellular receptors to mediate virus entry into cells. This is achieved by the fusion of the viral envelope with the plasma membrane. Similarly, viral glycoproteins expressed on cell surfaces mediate cell-to-cell fusion and facilitate virus spread. An interactive complex of viral glycoproteins gB, gD/gH/gL, and gK and other proteins mediate these membrane fusion phenomena with glycoprotein B (gB), the principal membrane fusogen. The requirement for the virion to enter neuronal axons suggests that the heterodimeric protein complex of gK and membrane protein UL20, found only in alphaherpesviruses, constitute a critical determinant for neuronal entry. This hypothesis was substantiated by the observation that a small deletion in the amino terminus of gK prevents entry into neuronal axons while allowing entry into other cells via endocytosis. Cellular receptors and receptor-mediated signaling synergize with the viral membrane fusion machinery to facilitate virus entry and intercellular spread. Unraveling the underlying interactions among viral glycoproteins, envelope proteins, and cellular receptors will provide new innovative approaches for antiviral therapy against herpesviruses and other neurotropic viruses.

28 October 2013 in Virology Journal
Verified
Journal Article
Open access
PDF file
AIArun V Iyer
Arun V Iyer
BPBapi Pahar
Bapi Pahar
VCVladimir N. Chouljenko
Vladimir N. Chouljenko
JWJason D Walker
Jason D Walker
Brent A. StanfieldBrent A. Stanfield
Brent A. Stanfield
KKKonstantin G Kousoulas
Konstantin G Kousoulas
Herpes simplex virus type-1(HSV-1) and HSV-2 are important human pathogens that cause significant ocular and urogenital complications, respectively. We have previously shown that HSV-1 virions lacking glycoprotein K (gK) are unable to enter into neurons via synaptic axonal membranes and be transported in either retrograde or anterograde manner. Here, we tested the ability of HSV-1 (F) gK-null to protect against lethal challenge with either highly virulent ocular HSV-1 (McKrae strain), or genital HSV-2 (G strain). The gK-null virus vaccine efficiently protected mice against lethal vaginal infection with either HSV-1(McKrae) or HSV-2 (G).

13 June 2012 in Virology Journal
Verified
Journal Article
Open access
PDF file
SCSona Chowdhury
Sona Chowdhury
MNMisagh Naderi
Misagh Naderi
VCVladimir N. Chouljenko
Vladimir N. Chouljenko
JWJason D Walker
Jason D Walker
KKKonstantin G Kousoulas
Konstantin G Kousoulas
Background: Herpes simplex virus type-1 (HSV-1) enters into cells via membrane fusion of the viral envelope with plasma or endosomal membranes mediated by viral glycoproteins. HSV-1 virions attach to cell surfaces by binding of viral glycoproteins gC, gD and gB to specific cellular receptors. Here we show that the human ocular and highly neurovirulent HSV-1 strain McKrae enters substantially more efficiently into cells via the gB-specific human paired immunoglobulin-like type-2 receptor-α (hPILR-α). Comparison of the predicted amino acid sequences between HSV-1(F) and McKrae strains indicates that amino acid changes within gB, gC, gH and gL may cause increased entry via the hPILR- α receptor. Results: HSV-1 (McKrae) entered substantially more efficiently than viral strain F in Chinese hamster ovary (CHO) cells expressing hPIRL-α but not within CHO-human nectin-1, -(CHO-hNectin-1), CHO-human HVEM (CHO-hHVEM) or Vero cells. The McKrae genes encoding viral glycoproteins gB, gC, gD, gH, gL, gK and the membrane protein UL20 were sequenced and their predicted amino acid (aa) sequences were compared with virulent strains F, H129, and the attenuated laboratory strain KOS. Most aa differences between McKrae and F were located at their gB amino termini known to bind with the PILRα receptor. These aa changes included a C10R change, also seen in the neurovirulent strain ANG, as well as redistribution and increase of proline residues. Comparison of gC aa sequences revealed multiple aa changes including an L132P change within the 129-247 aa region known to bind to heparan sulfate (HS) receptors. Two aa changes were located within the H1 domain of gH that binds gL. Multiple aa changes were located within the McKrae gL sequence, which were preserved in the H129 isolate, but differed for the F strain. Viral glycoproteins gD and gK and the membrane protein UL20 were conserved between McKrae and F strains. Conclusions: The results indicate that the observed entry phenotype of the McKrae strain is most likely due to a combination of increased binding to heparan sulfate receptors and enhanced virus entry via gB-mediated fusion of the viral envelope with plasma membranes.

14 April 2018 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
RSRahul Sharma
Rahul Sharma
PSPushpendra Singh
Pushpendra Singh
MPMaria Pena
Maria Pena
RSRamesh Subramanian
Ramesh Subramanian
VCVladimir N. Chouljenko
Vladimir N. Chouljenko
RTRichard W. Truman
Richard W. Truman

24 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
FMFarhana Musarrat
Farhana Musarrat
VCVladimir N. Chouljenko
Vladimir N. Chouljenko
RNRafiq Nabi
Rafiq Nabi
ADAchyut Dahal
Achyut Dahal
SJSeetharama Jois
Seetharama Jois
KKKonstantin G Kousoulas
Konstantin G Kousoulas
Coronaviruses belong to a group of enveloped, positive-single stranded RNA viruses that are known to cause severe respiratory distress in animals and humans. The current SARS coronavirus-2 (SARS CoV-2) pandemic has caused more than 2,000,000 infections globally and nearly 200,000 deaths. Coronaviruses enter susceptible cells via fusion of the viral envelope with the plasma membrane and/or via fusion of the viral envelope with endosomal membranes after endocytosis of the virus into endosomes. Previous results with SARS and MERS CoV have shown that the Spike (S) glycoprotein is a major determinant of virus infectivity and immunogenicity. Herein, we show that expression of SARS CoV-2 S (S-n) glycoprotein after transient transfection of African green monkey kidney (Vero) cells caused extensive cell fusion in comparison to limited cell fusion caused by the SARS S (S-o) glycoprotein. S-n expression was detected intracellularly and on transfected Vero cell surfaces and caused the formation of very large multinucleated cells (syncytia) by 48 hours post transfection. These results are in agreement with published pathology observations of extensive syncytial formation in lung tissues of COVID-19 patients. This differential S-n versus S-o-mediated cell fusion suggests that SARS-CoV-2 is able to spread from cell-to-cell much more efficiently than SARS effectively avoiding extracellular spaces and neutralizing antibodies. A systematic screening of several drugs for ability to inhibit S-n and S-o cell fusion revealed that the FDA approved HIV-protease inhibitor, nelfinavir mesylate (Viracept) drastically inhibited S-n and S-o-mediated cell fusion in a dose-dependent manner. Complete inhibition of cell fusion was observed at a 10 micromolar concentration. Computational modeling and in silico docking experiments suggested the possibility that nelfinavir may bind inside the S trimer structure, proximal to the S2 amino terminus directly inhibiting S-n and S-o-mediated membrane fusion. Also, it is possible that nelfinavir mesylate acts on cellular processes to inhibit S proteolytic processing. These results warrant further investigations of the potential of nelfinavir mesylate as an antiviral drug, especially at early times after SARS-CoV-2 symptoms appear.

11 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MHMohammed Tanveer Hussain
Mohammed Tanveer Hussain
KFKiran Fida
Kiran Fida
AAAmber A. Anderson
Amber A. Anderson
MRMd. Mostafijur Rahman
Md. Mostafijur Rahman
VCVladimir N. Chouljenko
Vladimir N. Chouljenko
Brent A. StanfieldBrent A. Stanfield
Brent A. Stanfield
Cervical cancer is a major cause of mortality worldwide and has been attributed to long-lasting (persistent) infections with the human papillomavirus (HPV). Although more than 50 types of HPVs are known the infect the genital tract, fewer than a dozen of them are regularly linked to cervical cancers leading to these types being designated as “high risk” HPVs. Worldwide, over 90% of cervical cancers arise from persistent high-risk human papillomavirus (HPV) infection and the infectious nature of the virus procures the need for preventative vaccines against cervical cancer. To address this, we have developed a live-attenuated herpes simplex virus type 1 (HSV-1) VC2-vectored vaccine expressing a catalytically inactive mutant of HPV-16 E7 (E7m) fused to the viral capsid protein VP26. Incorporation of E7m into the VC2 backbone resulted in stable incorporation of VP26-E7m fusion protein in cell free viral particles and detectable intracellular expression within infected cells. The recombinant virus (E7m VC-2) maintained growth kinetics comparable to parental VC2 in vitro, though plaque size was modestly reduced, suggesting a minimal fitness cost associated with transgene insertion. To evaluate prophylactic efficacy, mice received a one-dose vaccine schedule of E7m VC-2 prior to challenge with syngeneic HPV-16 E6/E7-expressing tumor cells. In mice that did develop tumors, growth kinetics were attenuated relative to unvaccinated animals. Importantly, neither E7m VC-2 nor adjuvanted E7m protein alone achieved statistically significant protection versus untreated controls. Immunohistochemical analysis of tumor tissue revealed markedly increased CD8+ T cell infiltration in E7m VC-2 vaccinated mice, demonstrating that vaccination promotes a cytotoxic immune microenvironment capable of restricting tumor progression. Three-dose vaccination of mice with E7m VC-2 induced a robust Th1-polarized immune response characterized by strong interferon-gamma (IFN-γ) secretion in response to HPV16 E7 expressing syngeneic cell lines, consistent with the induction of cell-mediated antitumor immunity and superior to responses elicited by adjuvanted E7m protein alone. With an extended three-dose vaccination schedule E7m VC-2 conferred significantly greater protection against tumor establishment relative to untreated controls (80% vs. 20% tumor-free). Collectively, these findings establish proof-of-concept for the HSV-1 VC2 platform as an effective vector for HPV-targeted cancer immunotherapy, delivering statistically significant prophylactic protection alongside potent induction of tumor-reactive CD8+ T cells. Future studies will incorporate both E6 and E7 antigens to broaden antigenic coverage, evaluate therapeutic efficacy in established tumor models, and optimize dosing regimens with the long-term goal of advancing this Louisiana-developed platform toward IND-enabling studies and clinical translation.